In the small set of cases harboring molecular aberrations in EGFR and ALK included in this study, the null or heterogeneous p16Ink4A immunohistochemical expression conferred a poor prognosis, suggesting that the assessment of p16Ink4A protein status might help to tailor the prognostic evaluation of EGFR or ALK aberrant lung cancers. Here, ALK is linked to lung cancer.